| Title | Interim 2024/25 influenza vaccine effectiveness: eight European studies, September 2024 to January 2025 / |
|---|---|
| Authors | Rose, Angela MC ; Lucaccioni, Héloïse ; Marsh, Kimberly ; Kirsebom, Freja ; Whitaker, Heather ; Emborg, Hanne-Dorthe ; Bolt Botnen, Amanda ; O’Doherty, Mark G ; Pozo, Francisco ; Hameed, Safraj Shahul ; Andrews, Nick ; Hamilton, Mark ; Trebbien, Ramona ; Lauenborg Møller, Karina ; Marques, Diogo FP ; Murphy, Siobhan ; McQueenie, Ross ; Lopez-Bernal, Jamie ; Cottrell, Simon ; Bucholc, Magda ; Kissling, Esther |
| DOI | 10.2807/1560-7917.ES.2025.30.7.2500102 |
| Full Text |
|
| Is Part of | Eurosurveillance.. Stockholm : European Centre for Disease Control and Prevention (ECDC). 2025, vol. 30, iss. 7, art. no. 2500102, p. [1-11].. eISSN 1560-7917 |
| Abstract [eng] | The 2024/25 influenza season in Europe is currently characterised by co-circulation of influenza A(H1N1)pdm09, A(H3N2) and B/Victoria viruses, with influenza A(H1N1)pdm09 predominating. Interim vaccine effectiveness (VE) estimates from eight European studies (17 countries) indicate an all-age influenza A VE of 32–53% in primary care and 33–56% in hospital settings, with some signals of lower VE by subtype and higher VE against influenza B (≥ 58% across settings). Where feasible, influenza vaccination should be encouraged and other prevention measures strengthened. |
| Published | Stockholm : European Centre for Disease Control and Prevention (ECDC) |
| Type | Journal article |
| Language | English |
| Publication date | 2025 |
| CC license |
|